---
layout: default
title: Fluorometholone
parent: 僅模型預測 (L5)
nav_order: 362
evidence_level: L5
indication_count: 10
---

# Fluorometholone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fluorometholone: From Inflammatory Conjunctivitis to Postinfectious Vasculitis

## One-Sentence Summary

Fluorometholone is a topical ophthalmic corticosteroid established for treating inflammatory conjunctivitis. The TxGNN model predicts it may be effective for **Postinfectious Vasculitis**, but this prediction is currently supported by **0 clinical trials** and **0 publications** — it is a pure model-generated signal with no corroborating evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Inflammatory conjunctivitis (per DrugBank pharmacology data; formal Taiwan-approved indication text not yet retrieved) |
| Predicted New Indication | Postinfectious Vasculitis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Taiwan Market Status | 未上市 (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed official mechanism-of-action (MOA) data has not yet been retrieved from TFDA (data gap DG002). Based on available DrugBank pharmacology annotations, fluorometholone is a synthetic fluorinated corticosteroid that acts as a **glucocorticoid receptor (NR3C1) agonist**, and its established clinical use is topical anti-inflammatory treatment of inflammatory conjunctivitis.

Postinfectious vasculitis, however, is a systemic inflammatory blood-vessel disease that typically requires systemic immunomodulatory treatment. Fluorometholone is formulated and used exclusively as a topical ophthalmic drug with very low systemic absorption. This creates a categorical mismatch between the drug's actual delivery route/exposure profile and the systemic reach a vasculitis indication would require.

Given this mismatch, the mechanistic plausibility of this specific prediction is weak. The high TxGNN score (99.91%) reflects a strong pattern-based signal from the knowledge graph, but it is not corroborated by any clinical trial or published literature — this is why the evidence level is rated L5 (model prediction only). Notably, within this same candidate set, rank #2 ("post-bacterial disorder") has a materially stronger evidentiary basis, including an active Phase 2 trial testing fluorometholone directly (see Conclusion).

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Taiwan Market Information

Fluorometholone is currently not approved/marketed in Taiwan (0 registrations on file); no license records are available to summarize.

---

## Safety Considerations

- **Drug Interactions**: DDInter flags 11 potential interacting drugs (Doxycycline, Salbutamol, Cyclosporine, Acetaminophen, Digoxin, Brimonidine, Cephalexin, Alendronic acid, Acyclovir, Diazepam, Fenofibrate). All are recorded with **severity level "Unknown"** — the interaction is flagged in the database but not yet mechanistically or clinically characterized, so each would need individual review before co-administration decisions are made.

Please refer to the package insert for other safety information (key warnings and contraindications data are not yet available — TFDA label retrieval is a blocking data gap, DG001).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The postinfectious vasculitis prediction has no clinical trial or literature support (L5, model-only), and the proposed systemic indication is mechanistically inconsistent with fluorometholone's topical, low-systemic-absorption profile. The drug is also not currently marketed in Taiwan, and TFDA safety labeling data needed for a Stage 1 safety review is still missing (DG001, blocking).

**To proceed, the following is needed:**
- TFDA package insert (warnings/contraindications) — currently a blocking data gap
- Confirmed official MOA documentation (DrugBank query pending, DG002)
- Preclinical or mechanistic data establishing a plausible systemic exposure pathway relevant to vasculitis
- Consider redirecting evaluation effort toward **"post-bacterial disorder"** (rank #2 in this same candidate set), which has a materially stronger evidence base — one completed Phase NA trial (n=154) and one enrolling Phase 2 trial (NCT07308938, n=174) directly testing topical fluorometholone as adjunct anti-inflammatory therapy for bacterial corneal ulcers/post-surgical inflammation, rated evidence level L2.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

